3. How can the medical director test whether a convenient service has sufficient oversight?
Title: Online Prescribing of GLP-1 Receptor Agonists, Alcohol-Related Liver Disease, Survival After Lung Transplant for Select Lung Cancer Patients, and More
Listen: JAMA episode and transcript
Who and when: JAMA deputy editors Linda Brubaker, MD, and Preeti Malani, MD. July 10, 2026; 13 minutes, 5 seconds. Evidence: transcript-backed, with the transcript labelled automatically generated. Episode metadata.
Key takeaways: The GLP-1 segment discusses a secret-shopper study of online prescribing, including limited clinician engagement, weak verification of previous treatment and insufficient coordination of care. The editors distinguish easy access from adequate clinical oversight. The episode also covers unrelated research, so it is not wholly devoted to GLP-1s. Transcript. (edhub.ama-assn.org)
Our procurement application: Have the medical director review a partner’s actual onboarding and escalation workflow—not just its promised turnaround time. Request examples of how missing history, conflicting prescriptions and clinical questions stop or redirect an order.
Limitation: The discussion does not assess your shortlisted suppliers, and the study findings should not be applied indiscriminately to every telehealth service.
4. How should clinical developments inform access planning?
Title: GLP Practice Insights: New Agents, New Data, and New Access Opportunities (CE)
Listen: ASHP episode page
Who and when: Jiwoo Lee, PharmD, and Natalie Rodriguez, PharmD, of Temple University School of Pharmacy; Paris Smith, PharmD, of Parkview Health. June 20, 2026. Evidence: publisher-notes-backed. Speaker details.
Key takeaways supported by the description: The episode covers new formulations, emerging clinical uses, access and affordability. Its role in this list is clinical horizon scanning rather than operational pharmacy comparison. The accessible notes do not support a more detailed account of particular recommendations. ASHP overview.
Our procurement application: Ask clinical leadership which changes would require new prescribing fields, patient education, benefit checks or pharmacy capabilities. Keep speculative future requirements separate from products and workflows approved for implementation now.
Limitation: Secondary priority for procurement. ASHP explicitly says the presenters’ views are not its official policy or a product endorsement. ASHP disclaimer.
5. Does manufacturer-direct access necessarily mean excluding local pharmacies?
Title: Manufacturer Direct D2C and the Future of Independent Pharmacy
Listen/read: IPC episode, player and transcript
Who and when: Todd Eury hosts Shelley Bailey of Independent Pharmacy Cooperative and Sammy Salem, principal owner and COO of Vios Health. The IPC page is dated October 8, 2026; this is a page date, not a verified first-release date. Evidence: transcript-backed. IPC sponsors the episode. Episode page.
Key takeaways: The speakers describe manufacturer-supported access through participating independent pharmacies, rather than treating direct access and community dispensing as mutually exclusive. They discuss patient affordability, pharmacy acquisition economics, reimbursement and patients facing coverage barriers. These are the participants’ programme descriptions and assessments. Transcript.
Our procurement application: Ask each prospective pharmacy whether it participates in relevant programmes, for which products and patients, and with what documentation. Require a worked patient journey showing payment, dispensing, exceptions and support ownership.
Limitation: Do not translate favourable pharmacy economics into guaranteed clinic savings, patient eligibility or nationwide availability.
6. What should a clinic inspect beyond the pharmacy’s quoted price?
Title: The Pharma Direct-to-Consumer Shift: Moving Faster Than Infrastructure Can Handle
Listen: Podcast episode
Read: Original publisher’s detailed recap
Who and when: Ryan Kelly, identified as Rx-360’s interim CEO and senior director of supply-chain security and brand protection. April 6, 2026; approximately 27 minutes. Evidence: detailed publisher-recap-backed. Episode metadata.
Key takeaways: Kelly argues for extending supplier qualification downstream to dispensing partners. The recap identifies state licensing, cold-chain capability, quality systems, fragmented data and last-mile delivery as diligence topics. He also favours iterative implementation over launching at full scale immediately. Publisher recap.
Our procurement application: Translate the discussion into a controlled pilot: agreed order-status reporting, temperature-excursion escalation, failed-delivery handling and a named owner for each handoff. Test exceptions as well as successful orders.
Limitation: The discussion primarily addresses manufacturers. Applying its framework to a 20–60-prescriber clinic is our analytical adaptation, not a clinic case study presented by the speaker.
7. What can a CFO learn from pharmacy-benefit procurement without confusing it with clinic purchasing?
Title: AH104 — Biosimilars, GLP-1s, PBM Reform, and Other 2026 Pharmacy Drivers, with Bridget Mulvenna
Listen: Astonishing Healthcare episode and chapter guide
Who and when: Host Justin Venneri and Bridget Mulvenna, Judi Health’s vice president of national business development. April 3, 2026. Evidence: detailed publisher-notes-backed; vendor-produced. Episode page.
Key takeaways: The discussion challenges procurement comparisons built only around unit prices and rebates. It examines drug mix, utilisation controls and GLP-1 access economics. Useful published chapter starts are 06:44 for procurement, 17:12 for lower rebates and 20:45 for GLP-1 pricing and pipeline issues. Chapter guide.
Our procurement application: Build separate columns for clinic expenditure, patient payments and insurer expenditure. Ask which party actually receives any proposed saving.
Limitation: Employer PBM procurement is not clinic medicine purchasing. Do not import the speaker’s interpretation of prior-authorisation approval rates as evidence of care quality; that requires separate clinical and access review.
Sources cited on this page
- edhub.ama-assn.org · Source 1 ↗https://edhub.ama-assn.org/jn-learning/audio-player/19077724
- ashp.org · Source 2 ↗https://www.ashp.org/professional-development/ashp-podcasts/clinical-conversations/2026/glp-practice-insights-new-agents-new-data-and-new-access-opportunities
- ipcrx.com · Source 3 ↗https://www.ipcrx.com/pharmacy-podcasts/manufacturer-direct-d2c-and-the-future-of-independent-pharmacy/
- podcasts.apple.com · Source 4 ↗https://podcasts.apple.com/ie/podcast/the-pharma-direct-to-consumer-shift-moving-faster/id1676259280?i=1000759494894
- pharmasource.global · Source 5 ↗https://pharmasource.global/content/podcast/why-pharmas-direct-to-consumer-shift-is-moving-faster-than-infrastructure-can-handle/
- judi.health · Source 6 ↗https://www.judi.health/insights/ah104---biosimilars-glp-1s-pbm-reform-and-other-2026-pharmacy-drivers-with-bridget-mulvenna